rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2009-5-2-79-82rpcardio-640Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯCARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRILКАРДИОПРОТЕКТИВНЫЕ И НЕФРОПРОТЕКТИВНЫЕ СВОЙСТВА ИНГИБИТОРА АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА РАМИПРИЛАНапалковД. А.NapalkovD. A.

119991 Москва, ул. Б. Пироговская, д. 6

Bolshaya Pirogovskaya ul. 6, Moscow, 119991

dminap@mail.ruГоловенкоЕ. Н.GolovenkoE. N.

119991 Москва, ул. Б. Пироговская, д. 6

Bolshaya Pirogovskaya ul. 6, Moscow, 119991

Московская медицинская академия имени И.М.СеченоваРоссияMoscow Medical Academy named after I.M.SechenovRussian Federation200909012016527982Copyright © Napalkov D.A., Golovenko E.N., 20162016Напалков Д.А., Головенко Е.Н.Napalkov D.A., Golovenko E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/640

There is grate interest to ACE inhibitors which have cardioprotective and neproprotective effects. Ramipril efficacy in ischemic heart disease prevention as well as ramipril positive effect on myocardium in adolescents is presented on the base of some trails. Ramipril ability to delay of diabetic and non-diabetic nephropathy progression is also discussed.

В настоящее время сохраняется большой интерес к группе ингибиторов АПФ, обладающих кардио- и нефропротективным эффектами. В статье на примере ряда исследований показана эффективность рамиприла при профилактике ишемической болезни сердца, а также его позитивное влияние на состояние миокарда у подростков. Отмечена также способность рамиприла тормозить прогрессирование заболевания почек как диабетической, так и недиабетической природы.

рамиприлингибитор АПФартериальная гипертензияальбуминуриягипертрофия левого желудочкафибрилляция предсердийramiprilACE inhibitorarterial hypertensionalbuminurialeft ventricle hypertrophyatrial fibrillationReferencesSeeman T., Gilík J., Vondrák K. et al. Regression of left-ventricle hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens 2007;20(9):990-6.Seeman T., Gilík J., Vondrák K. et al. Regression of left-ventricle hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens 2007;20(9):990-6.Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90(4):2056-69.Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90(4):2056-69.Yusuf S., Pepine C.J., Garces C. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340(8829):1173-8.Yusuf S., Pepine C.J., Garces C. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340(8829):1173-8.Pfeffer M.A., Braunwald E., Моуё L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327(10):669-77.Pfeffer M.A., Braunwald E., Моуё L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327(10):669-77.Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.Tu К., Mamdani M.M., Jacka R.M. et al. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003;168(5):553-7.Tu К., Mamdani M.M., Jacka R.M. et al. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003;168(5):553-7.Pilote L., Abrahamowicz M., Rodrigues E. et al. Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect? Ann Intern Med 2004;141(2):102- 12.Pilote L., Abrahamowicz M., Rodrigues E. et al. Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect? Ann Intern Med 2004;141(2):102- 12.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. AIRE Study Investigators. Lancet 1993; 342(8875):821-8.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. AIRE Study Investigators. Lancet 1993; 342(8875):821-8.Hall A.S., Murray G.D., Ball S.G. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997;349(9064):1493-97.Hall A.S., Murray G.D., Ball S.G. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997;349(9064):1493-97.Pfeffer M.A., Greaves S.C., Arnold J.M. et al. Early versus delayed angiotensinconverting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997;95(12):2643-51.Pfeffer M.A., Greaves S.C., Arnold J.M. et al. Early versus delayed angiotensinconverting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997;95(12):2643-51.Beluzzi F., Sernesi L., Preti P. et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009;53(1):24-9.Beluzzi F., Sernesi L., Preti P. et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009;53(1):24-9.Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). J 1982;285(6343):685- 89.Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). J 1982;285(6343):685- 89.Parving H.H., Andersen A.R., Smidt U.M., Swendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1(8335):1175-9.Parving H.H., Andersen A.R., Smidt U.M., Swendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1(8335):1175-9.Björck S., Mulec H., Johnsen S.A. et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304(6823):339-43.Björck S., Mulec H., Johnsen S.A. et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304(6823):339-43.Parving H.H., Hommel E., Smidt U.M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988;297(6656):1086-91.Parving H.H., Hommel E., Smidt U.M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988;297(6656):1086-91.Lewis E.J., Hunsicker L.G., Bain R.P., Rohde E.D. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329(20):1456-62.Lewis E.J., Hunsicker L.G., Bain R.P., Rohde E.D. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329(20):1456-62.Kasiske B.L., Kalil R.S., Ma J.Z. et al. Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118(2):129-38.Kasiske B.L., Kalil R.S., Ma J.Z. et al. Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118(2):129-38.Weidmann P., Schneider M., Böhlen L. Therapeutic efficacy of different antihypertensive drugs inhuman diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995;10(Suppl 9):39-45.Weidmann P., Schneider M., Böhlen L. Therapeutic efficacy of different antihypertensive drugs inhuman diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995;10(Suppl 9):39-45.O'Hare P., Bilbous R., Mitchell T. et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension. The ATLANTIS study group. Diabetes Care 2000;23(12):1823-9.O'Hare P., Bilbous R., Mitchell T. et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension. The ATLANTIS study group. Diabetes Care 2000;23(12):1823-9.Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495.Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495.Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACEinhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354(9175):359-64.Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACEinhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354(9175):359-64.Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998;352(9136):1252-6.Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998;352(9136):1252-6.

The authors declare that there are no conflicts of interest present.